PREVALENCE of AmpC β-LACTAMASE IN PLASMID RESISTANT GENE FROM UTI CLINICAL ISOLATES BY MOLECULAR TECHNIQUES
AbstractObjective: To detect the prevalence of Plasmid resistant AmpC β-lactamases gene in clinical isolates of gram negative organisms from UTI patients which produce resistance against multiple antibiotics. The gene coding for AmpC β-lactamases is also present in E. coli & Klebsiella species was not expressed because due to lack of promoter region, but the transfer of chromosomal genes to plasmids allows the expression of AmpC β-lactamases that hydrolyze the β-lactam ring, which has greater impact on resistance against multi-drug antibiotics, is a significant problem around the world. Methods: Among 20 non-repetitive clinical isolate of each Escherichia coli and Klebsiella pneumoniae, examined for identification and characterization of urine cultures based on morphological, biochemical tests, antibiotic resistant pattern, modified-disc method and detection of AmpC gene by plasmid identification by agarose gel electrophoresis and amplification of AmpC gene by PCR techniques. Results: The study detects the prevalence of AmpC gene primarily by modified disc inducer method as well as conformational molecular analysis by PCR amplification techniques. AmpC prevalence was observed in both strains from the UTI clinical isolates. The prevalence of AmpC resistance may differ due to the geographical variations was observed in different strains of gram negative organisms. Conclusion: The detection of AmpC resistance mechanism in plasmid DNA is an important factor to improve the clinical management of infection against higher antibiotics in relation with antibiotic resistance and cost of antibiotics which could help in therapeutics and UTI control process.
Article Information
33
4784-4793
556
984
English
IJPSR
S. Singh, S. Gopalakrishnan and N. Karthikeyan *
Department of Pharmaceutical Biotechnology, College of Pharmacy, SRIPMS, Tamil Nadu, India.
keyanpharma@gmail.com
21 February, 2018
07 May, 2018
13 May, 2018
10.13040/IJPSR.0975-8232.9(11).4784-93
01 Novembers, 2018